BioSpace News Archive

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

The patent pertains to a specialized 3D x-ray filter, known as a 3D-Beam Modulation Filter, that is designed to tailor the shape of the IzoView x-ray beam to match the shape of the patient’s breast being scanned.

Kintor Pharmaceutical Limited today announced the primary endpoint of phase II clinical trial of pyrilutamide (“KX-826", tincture) in China for the treatment of androgenetic alopecia (AGA)

Intrommune Therapeutics, Inc. announced the appointment of Stuart Loesch as its new Chief Commercial Officer.

Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.

The FDA has granted Madorra breakthrough device designation for the company’s non-invasive, home-use device for a subset of women experiencing moderate to severe vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).

CELLIANT®, infrared responsive technology from materials science trailblazer Hologenix, has completed its 9th peer-reviewed published study.

Nimble Therapeutics, an industry-leading peptide therapeutic discovery and optimization company, today announced the appointment of Dr. Cyrus Arman as Chief Business Officer.

Eyam Vaccine and Immunotherapeutics (EYAM), a next-generation vaccine biotechnology company, announced today an agreement with Veristat, a scientific-minded, global clinical research organization (CRO), to plan and coordinate clinical trials of their vaccine program against SARS-CoV-2.